Emerging Trends: Novel Molecular Targets and Moving Beyond Acute Symptoms in Bipolar Depression
J Clin Psychiatry 2014;75(7):e17
© Copyright 2017 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Depression is the predominant phase of bipolar illness, but it still represents the greatest unmet need for the treatment of this condition. Few agents are approved to treat bipolar depression, and research into long-term treatment is lacking, especially for patients whose index episode is depression. Drugs commonly used to treat bipolar depression include antidepressants, antipsychotics, and mood stabilizers, but many of these agents are ineffective or have the potential to cause intolerable or serious side effects. Investigators looking for new treatments are exploring numerous molecular therapeutic targets. Some of these targets are familiar, such as dopamine agonism and glutamatergic modulation, but others are novel, such as protein kinase C regulation or melatonin agonism. Potential new agents hold promise for improving the treatment of not only acute depressive episodes but also long-term maintenance treatment of bipolar disorder.
See the entire activity.